NASDAQ$TVTX
Travere Therapeutics Inc · Q4 2024 earnings
Q4 2024 earnings · · After market close · Investor relations
Briefing
Travere Therapeutics reported strong financial results for the fourth quarter and full year 2024, driven by the successful commercial launch of FILSPARI and progress in its clinical pipeline.
Travere Therapeutics delivered a strong performance in Q4 2024, with total revenue reaching $74.787 million, significantly up from the previous year. The company's net product sales, particularly from FILSPARI, were a key driver of this growth. Despite an operating loss, the company maintained a healthy cash position and is advancing its key programs, including the sNDA submission for FILSPARI in FSGS and the restart of enrollment for pegtibatinase.
- Net product sales for Q4 2024 reached $73.546 million, a substantial increase from $39.916 million in Q4 2023.
- FILSPARI net product sales alone contributed $49.644 million in Q4 2024, demonstrating strong commercial launch success.
- The company reported a net loss of $60.264 million for Q4 2024, an improvement from a $90.173 million net loss in Q4 2023.
- Cash, cash equivalents, and marketable securities stood at $370.7 million as of December 31, 2024, including $134.7 million from a common stock offering.
Headline financials
Revenue & EPS history
Travere · Revenue · Quarterly
$74.8M
Revenue by segment
Travere · $33.9M total across 2 segments · Q3 2023
- Tiopronin products$25.9M+2.0%76.3%
- FILSPARI$8.04M—23.7%
Forward guidance
Travere Therapeutics is focused on advancing FILSPARI for FSGS, optimizing pegtibatinase manufacturing, and restarting its pivotal program, while also anticipating milestones from its IgAN programs and collaborations.
Tailwinds
- On track to submit sNDA for FILSPARI in FSGS around the end of 1Q 2025, aiming for traditional approval.
- Preparing for a successful launch of FILSPARI for FSGS, if approved, which would be the first and only approved medicine for FSGS.
- Continuing to optimize manufacturing for pegtibatinase and on track to restart enrollment in the Phase 3 HARMONY Study in 2026.
- Anticipates final publication of updated KDIGO clinical guidelines for IgAN in 2025, recommending FILSPARI as a foundational kidney-targeted therapy.
- Expects to receive a $17.5 million milestone payment from CSL Vifor upon conversion of CMA to full approval for FILSPARI in Europe.
Headwinds
- No guarantee that the FDA will accept the sNDA for filing, grant priority review, or grant approval of FILSPARI for FSGS.
- Risks associated with the regulatory review and approval process for new indications and modifications.
- Challenges related to manufacturing scale-up for pegtibatinase and potential delays in restarting clinical trials.
- Uncertainties regarding market acceptance of commercial products, including efficacy, safety, price, reimbursement, and benefit over competing therapies.
- Risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory, or other reasons.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q4 2024
-0.6%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-0.3%
Avg return
30 days after
49%
25 / 51 earnings
Positive
+16.6%
Q3 2025
Best reaction
-16.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +4.8% | -5.1% | +2.8% | |
| Q4 2025 | +3.1% | +0.1% | -8.4% | |
| Q3 2025 | +16.6% | +13.7% | +19.4% | |
| Q1 2025 | +1.6% | -2.6% | -27.6% | |
| Q4 2024 | -6.8% | -10.8% | -12.9% | |
| Q3 2024 | -1.1% | -0.0% | +5.9% | |
| Q2 2024 | -5.7% | -6.7% | -0.7% | |
| Q1 2024 | +7.8% | +0.6% | +25.1% | |
| Q4 2023 | -0.6% | +0.4% | -9.2% | |
| Q3 2023 | -4.7% | -16.0% | +30.3% | |
| Q2 2023 | -6.6% | -6.7% | -10.5% | |
| Q1 2023 | +5.6% | +4.2% | +19.7% | |
| Q4 2022 | +6.9% | +6.2% | +0.0% | |
| Q3 2022 | +3.1% | +0.5% | -12.4% | |
| Q2 2022 | +16.0% | +16.2% | +13.5% | |
| Q1 2022 | -14.2% | -13.2% | -6.4% | |
| Q4 2021 | +2.9% | +2.1% | -3.3% | |
| Q3 2021 | +10.0% | +15.1% | +10.8% | |
| Q2 2021 | -2.4% | +0.5% | +52.7% | |
| Q1 2021 | -16.6% | -17.4% | -41.2% | |
| Q4 2020 | -5.3% | -12.4% | -19.0% | |
| Q3 2020 | +1.6% | +11.4% | +18.1% | |
| Q2 2020 | -1.6% | -4.1% | -4.3% | |
| Q1 2020 | +7.6% | +0.8% | -0.9% | |
| Q4 2019 | -16.7% | -10.3% | -21.4% | |
| Q3 2019 | +4.4% | +8.0% | +20.7% | |
| Q2 2019 | -11.4% | -2.7% | -34.0% | |
| Q1 2019 | -7.9% | -5.5% | -2.7% | |
| Q4 2018 | +5.6% | +4.3% | +7.7% | |
| Q3 2018 | +0.6% | +1.2% | -4.4% | |
| Q2 2018 | -4.4% | -4.2% | +2.4% | |
| Q1 2018 | -5.2% | -5.7% | +11.6% | |
| Q4 2017 | +5.4% | +5.2% | -5.8% | |
| Q3 2017 | -13.4% | -16.3% | -17.1% | |
| Q2 2017 | -0.1% | +7.6% | +15.8% | |
| Q1 2017 | -4.4% | -6.5% | -7.1% | |
| Q4 2016 | +1.5% | -0.6% | -13.2% | |
| Q3 2016 | -4.3% | -1.2% | +8.5% | |
| Q2 2016 | +1.4% | -1.9% | -13.6% | |
| Q1 2016 | +5.2% | — | — | |
| Q4 2015 | -2.8% | — | — | |
| Q3 2015 | -10.0% | — | — | |
| Q2 2015 | +13.0% | — | — | |
| Q1 2015 | +5.8% | — | — | |
| Q4 2014 | +9.5% | — | — | |
| Q3 2014 | -14.4% | — | — | |
| Q2 2014 | -6.2% | — | — | |
| Q1 2014 | +4.9% | — | — | |
| Q4 2013 | +8.4% | — | — | |
| Q3 2013 | -5.8% | — | — | |
| Q2 2012 | -9.9% | — | — | |
| Q3 2012 | — | — | — | |
| Q1 2012 | — | — | — | |
| Q4 2012 | — | — | — | |
| Q3 2010 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro